IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2021 | $22.00 | Buy | Craig Hallum |
15-12G - Miromatrix Medical Inc. (0001527096) (Filer)
8-K - Miromatrix Medical Inc. (0001527096) (Filer)
EFFECT - Miromatrix Medical Inc. (0001527096) (Filer)
POS AM - Miromatrix Medical Inc. (0001527096) (Filer)
S-8 POS - Miromatrix Medical Inc. (0001527096) (Filer)
S-8 POS - Miromatrix Medical Inc. (0001527096) (Filer)
SC 14D9/A - Miromatrix Medical Inc. (0001527096) (Subject)
SC TO-T/A - Miromatrix Medical Inc. (0001527096) (Subject)
25-NSE - Miromatrix Medical Inc. (0001527096) (Subject)
SC 14D9/A - Miromatrix Medical Inc. (0001527096) (Subject)
3 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
4 - Miromatrix Medical Inc. (0001527096) (Issuer)
Craig Hallum initiated coverage of Miromatrix Medical with a rating of Buy and set a new price target of $22.00
SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13D - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G - Miromatrix Medical Inc. (0001527096) (Subject)
SC 13G - Miromatrix Medical Inc. (0001527096) (Subject)
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine
EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening conditions, and a pipeline that includes four ongoing registration-phase studies. The acquisition of Miromatrix will expand United Therapeutics' existing complementary platform of org
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening conditions, and a pipeline that includes four ongoing registration-phase studies. The acquisition of Miromatrix will expand United Therapeutics' existing complementary platform of organ manufacturing programs, which include ex-vivo lung perfusion, xenotransplantation, 3-D bioprinting, and rege
EDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement ("ISODP") Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort. M. Mason Macenski, Ph.D, Vice President Clinical and Regulatory Affairs, will be presenting on behalf of Miromatrix on Thursday, October 19 from 2:00pm – 3:00pm PDT. The presentation is titled Maximizing the gift of life: Using perfusion technology to bioe
EDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. Mr. Ross will deliver his re
EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on September 11th, 2023. Miromatrix Medical's management is scheduled to present at the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the webcast beginning Monday, September 11, 2023, at 7am ET, here. About MiromatrixMiromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplanta
EDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming Alliance for Regenerative Medicine (ARM) Tissue Engineering and Therapeutics Workshop held on September 6, 2023. Miromatrix Medical is scheduled to present at the ARM Tissue and Engineering and Therapeutics Workshop for three sessions: 9:00am ET: Bioengineering Transplantable Organs to Address the Transplant Need1:00pm ET: CMC Perspectives – Delivery, Stability, Potency3:30pm ET: Regulatory Perspectives The Al
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i
EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit
EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri
EDEN PRAIRIE, Minn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the expansion of the board and appointment of two new board members: Lisa Wipperman Heine and William P. Burke. "I am thrilled to welcome Lisa and Bill to the Miromatrix Board as we continue developing bioengineered organs to address the transplant shortage," said Jeff Ross, Ph.D., Miromatrix CEO. "Their experience in growing innovative companies and leveraging strategic partnerships make them exceptionally qualified to serve and furthe
EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and
EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update. "Miromatrix remains focused on gaining FDA clearance to initiate a Phase 1 clinical trial for miroliverELAP™ in order to treat patients suffering from acute liver failure," said Jeff Ross, Ph.D., Miromatrix CEO. "We remain on pace to submit a response to the FDA's clinical hold letter in the second half of 2023 relating to our miroliverELAP IND application; a key step towar
EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13738056. To li
EDEN PRAIRIE, Minn., March 31, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported fourth quarter and full year 2022 financial results and provided a corporate update. "Miromatrix is focused on providing patients with acute liver failure access to miroliverELAP™ as soon as possible," said Jeff Ross, Ph.D., Miromatrix CEO. "We are pioneering a new class of therapies with our bioengineered organs and believe that achieving FDA clearance to initiate a Phase 1 clinical trial for miroliverELAP will provide important validation
EDEN PRAIRIE, Minn., March 15, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the fourth quarter and full year 2022 after market close on Friday, March 31, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID:
EDEN PRAIRIE, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2022 financial results and provided a corporate update. "Miromatrix is excited to announce that we recently submitted our IND for miroliverELAP™," said Jeff Ross, Ph.D., Miromatrix CEO. "We believe this is the first IND to be submitted to the FDA for a bioengineered organ. I am incredibly proud of our entire team for achieving this important milestone and putting us one step closer to our goal of treating patients with our bioe
EDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2022 after market close on Monday, November 14, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13732863. To
EDEN PRAIRIE, Minn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2022 financial results and provided a corporate update. "Each quarter, Miromatrix makes meaningful progress towards our goal of improving the lives of transplant patients with our bioengineered organs," said Jeff Ross, Ph.D., Miromatrix CEO. "The need for viable transplant organs continues to grow and Miromatrix remains at the forefront of companies dedicated to developing alternatives to human-donor organ transplants". Busin